Table 1.
Baseline characteristics of all patients and those with KSHV-MCD alone and concurrent KSHV-associated diseases
| Baseline characteristics | All patients (N = 62) | MCD alone (n = 20) | MCD with concurrent KS (n = 34) | MCD with concurrent PEL±KS (n = 8) | P* |
|---|---|---|---|---|---|
| Age at MCD diagnosis, median (IQR), y | 44 (38-54) | 46 (44-54) | 41 (46-48) | 46 (29-56) | .07 |
| Sex, n (%) | |||||
| Cisgender male | 58 (94) | 19 (95) | 31 (91) | 8 (100) | 1.00 |
| Cisgender female | 4 (6) | 1 (5) | 3 (9) | 0 | |
| Race, n (%) | .87 | ||||
| White | 31 (50) | 10 (50) | 16 (47) | 5 (62) | |
| Hispanic | 5 (8) | 2 (10) | 3 (9) | — | |
| Black | 16 (26) | 6 (30) | 7 (20) | 3 (38) | |
| African immigrant | 7 (11) | 2 (10) | 5 (15) | — | |
| Other | 3 (5) | — | 3 (9) | — | |
| ECOG performance status, n (%) | |||||
| 0-2 | 43 (69) | 17 (85) | 23 (68) | 3 (38) | .05 |
| ≥3 | 19 (31) | 3 (15) | 11 (32) | 5 (62) | |
| HIV characteristics at MCD diagnosis | |||||
| Time from HIV diagnosis to MCD diagnosis, median (IQR), y | 4.5 (0.7, 11.5) | 12.8 (3.9, 18.9) | 2.8 (0.4, 7) | 3.1 (0.3, 8.4) | .002 |
| CD4 T-cell count, median (IQR), cells/µL | 180 (100, 302) | 227 (114, 500) | 126 (88, 246) | 252 (180, 371) | .14 |
| HIV viral load at MCD diagnosis, median (IQR), copies/mL | <50 (<50, 2599) | <50 (<50, 563) | 376 (<50, 2599) | 3648 (<50, 30773) | .77 |
| On ART, n (%) | 60 (97) | 18 (90) | 34 (100) | 8 (100) | .20 |
| KSHV-MCD characteristics | |||||
| Rituximab therapy prior to enrollment, n (%) | 20 (32) | 11 (55) | 7 (20) | 2 (25) | .04 |
| Number of flares treated, median (range) | 2 (1-5) | 2 (1-5) | 2 (1-5) | 2 (1-4) | .17 |
| Diagnosis of MCD made at NCI, n (%) | 27 (44) | 7 (35) | 15 (44) | 5 (63) | .39 |
| KS characteristics | |||||
| Any KS, n (%) | 41 (66) | — | 34 (100) | 7 (88) | .19 |
| T1 stage KS, n (%) of all patients with KS | 27 (66) | — | 20 (59) | 7 (100) | .22 |
| Time from KS diagnosis to MCD, median (IQR), mo | 1.3 (0, 40) | — | 0.4 (0, 20) | 40 (0, 60) | .3 |
| Prior chemotherapy for KS, n (%) | 21 (34) | — | 16 (50) | 5 (50) | 1.00 |
| Number of number of prior KS therapies, median (range) | 1 (1-3) | — | 1 (0-3) | 1 (0-2) | 1.00 |
ART, antiretroviral therapy.
*
P value comparisons of 3 groups were determined by Mehta’s modification to Fisher’s exact test and by exact Kruskal-Wallis or exact Wilcoxon rank sum test as appropriate.